The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > October 7, 2025
Daily News
October 7, 2025
- Inside Eylea - 2: Will a Bio-AG Return after Six Years? Pricing Debate Resumes
October 7, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
- Pharma Industry Generally Welcomes New LDP Leader Takaichi
October 7, 2025
- Boehringer Ingelheim Taps Marc Hasson to Lead Japan Operations
October 7, 2025
- Chugai CEO Lauds Sakaguchi’s Nobel-Winning Work
October 7, 2025
- Takaichi Vows Hospital Support via Extra Budget; MHLW Sees Boost for Funding Requests
October 7, 2025
- Alfresa, Kidswell, and Others to Form JV for Biosimilar Production in Japan
October 7, 2025
- Gilead Opens Japan Facility to Support CAR-T Delivery
October 7, 2025
- Datroway Hits Key Goals in Global PIII Trial for TNBC: Daiichi Sankyo
October 7, 2025
- SymBio Kicks Off Global PIII Trial of Brincidofovir in Europe
October 7, 2025
- Keytruda Maintains No. 1 Spot for 24th Straight Month: Encise
October 7, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…